Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) does not pay a cash dividend to its common stockholders, maintaining a dividend yield of zero percent. As a clinical-stage biopharmaceutical enterprise focused heavily on research, clinical trials, and developing its oral protein delivery platform, the firm reinvests all available financial capital into ongoing scientific operations.